@article {Thompson2020.07.27.20157594, author = {Andrew GB Thompson and Prodromos Anastasiadis and Ronald Druyeh and Ines Whitworth and Annapurna Nayak and Akin Nihat and Tze How Mok and Peter Rudge and Jonathan DF Wadsworth and Jonathan Rohrer and Jonathan M Schott and Amanda Heslegrave and Henrik Zetterberg and John Collinge and Graham S Jackson and Simon Mead}, title = {Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases}, elocation-id = {2020.07.27.20157594}, year = {2020}, doi = {10.1101/2020.07.27.20157594}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Prion diseases are fatal neurodegenerative conditions with highly accurate CSF and imaging diagnostic markers, but major unmet needs for blood biomarkers. Using ultrasensitive immuno-assays, we measured tau and neurofilament light chain (NfL) protein concentrations in 709 plasma samples taken from 377 individuals with prion disease during a 12-year prospective clinical study, alongside healthy and neurological control groups. This provides an unprecedented opportunity to evaluate their potential as biomarkers. Plasma tau and NfL were increased across all prion disease types. For distinguishing sCJD from control groups including clinically-relevant {\textquotedblleft}CJD mimics{\textquotedblright}, both show considerable diagnostic value. In sCJD, NfL was substantially elevated in every sample tested, including during early disease with minimal functional impairment and in all follow-up samples. Plasma tau was independently associated with rate of clinical progression in sCJD, while plasma NfL showed independent association with severity of functional impairment. In asymptomatic PRNP mutation carriers, plasma NfL was higher within 2 years of symptom onset than in samples taken earlier. We present biomarker trajectories for 9 individuals healthy at enrolment who developed symptoms during follow-up, showing potential for plasma NfL as a {\textquotedblleft}proximity marker{\textquotedblright}. We conclude that plasma tau and NfL have potential to fill key unmet needs for biomarkers in prion disease: as an outcome for clinical trials (NfL and tau); for predicting onset in at-risk individuals (NfL); and as an accessible test for earlier identification of patients that may have CJD and require more definitive tests (NfL). Further studies should evaluate their performance directly in these specific roles.Competing Interest StatementJ.C. is a Director and J.C., J.D.F.W. and G.S.J are shareholders of D-Gen Limited, an academic spin-out company working in the field of prion disease diagnosis, decontamination and therapeutics.Clinical TrialObservational cohort study not registered as a clinical trialFunding StatementFunding: This work was supported by the UK Medical Research Council, the National Institute for Health Research (NIHR), a Wellcome Trust Multi-User Equipment Grant, the Wolfson Foundation, the Department of Health (England), University College London Hospitals University College London NIHR Biomedical Research Centre, the UK Dementia Research Institute at UCL (540802), the European Research Council (681712), and by Alzheimers Research UK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Scotland MREC AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll Nfl and t-tau biomarker data is available (email s.mead{at}prion.ucl.ac.uk)}, URL = {https://www.medrxiv.org/content/early/2020/07/29/2020.07.27.20157594}, eprint = {https://www.medrxiv.org/content/early/2020/07/29/2020.07.27.20157594.full.pdf}, journal = {medRxiv} }